Monocyte-mediated enhancement of endometrial cell proliferation in women with endometriosis

Braun, Donald P.; Muriana, Adalberto; Gebel, Howard M.; Rotman, Carlos; Rana, Nasir; Dmowski, W. Paul

doi:10.1016/s0015-0282(16)56456-5

Cited by 84 publications

(40 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that CD44 is a well-known adhesion molecule that plays a determinant role in activation and homing of immune cells to sites of infl ammation [70] , it is conceivable that enhanced CD14+CD44+ blood monocytes are activated and recruited to the site of infl ammation in the peritoneal cavity. It was postulated that activated blood monocytes from patients with endometriosis could also promote the development of endometriotic lesions [71] . In agreement with this hypothesis, it was shown that endometrial cell proliferation is increased in vitro by peripheral monocytes from patients with endometriosis and suppressed by blood monocytes from healthy controls [71] .…”

Section: Immune Cellsmentioning

confidence: 99%

“…It was postulated that activated blood monocytes from patients with endometriosis could also promote the development of endometriotic lesions [71] . In agreement with this hypothesis, it was shown that endometrial cell proliferation is increased in vitro by peripheral monocytes from patients with endometriosis and suppressed by blood monocytes from healthy controls [71] .…”

Section: Immune Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Is Endometriosis Associated with Systemic Subclinical Inflammation?

Agic¹,

Xu²,

Finas³

et al. 2006

Gynecol Obstet Invest

208

132

View full text Add to dashboard Cite

Endometriosis is a pelvic inflammatory process with altered function of immune-related cells and increased number of activated macrophages in the peritoneal environment that secrete various local products, such as growth factors and cytokines. The elevation of cytokines and other factors in the peritoneal fluid is accompanied by the elevation of similar factors, such as CRP, SAA, TNF-α, MCP-1, IL-6, IL-8 and CCR1, in the peripheral blood of patients with endometriosis. CD44+ and CD14+ monocytes are significantly increased, while CD3+ T lymphocytes and CD20+ B lymphocytes show modest, but significant decrease in peripheral blood of women with endometriosis. This indicates that endometriosis could be viewed as a local disease with systemic subclinical manifestations. This review provides an overview of data on the changes of various factors in peripheral blood and their potential use as diagnostic tools in patients with endometriosis.

show abstract

Section: Immune Cellsmentioning

confidence: 99%

Section: Immune Cellsmentioning

confidence: 99%

Is Endometriosis Associated with Systemic Subclinical Inflammation?

Agic¹,

Xu²,

Finas³

et al. 2006

Gynecol Obstet Invest

208

132

View full text Add to dashboard Cite

show abstract

“…It should be noted that much insight onto the effectiveness of progestins (such as medroxyprogesterone acetate), GnRH-a (such as leuprolide acetate) and androgens (such as danazol) in suppression of endometriotic lesions was gained through the use of primary cell cultures derived from endometrial cells taken from women with endometriosis [75] as well as without [76][77][78] . After all, endometriosis is defined as the ectopic presence of endometrial glandular and stromal cells outside the uterine cavity [79] .…”

Section: Yhes Cell Line As a Model For Stromal Component Of Endometrimentioning

confidence: 99%

Inhibition of Proliferation of Endometrial Stromal Cells by Trichostatin A, RU486, CDB-2914, N-Acetylcysteine, and ICI 182780

Wu¹,

Guo²

2006

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: All current major medications in treating endometriosis are effective in treating pain, most likely through suppression of proliferation of the implants, yet their effectiveness is relatively short term and they all have many undesirable, and sometimes severe, side effects. There is pressing need for novel, more effective medications in treating endometriosis with less and/or milder side effects. Methods: Using a recently established immortalized endometrial stromal cell line, we carried out cell proliferation assays for cells treated with trichostatin A (TSA), RU486, CDB-2914, and N-acetylcysteine, and ICI 182780. Gene expression levels for PR-A, PR-B, AR, Fas and FasL were measured. Protein expression levels for ERα, ERβ, and AR were also measured. Results: Cell proliferation assay results for NAC, H₂O₂, CDB, and RU486 were nearly identical or similar to what have been reported based on primary cell cultures or in vivo studies. TSA, CDB, RU486 and NAC all had various antiproliferative effects. TSA had a more potent and longer lasting antiproliferative effect than CDB and NAC, even in the presence of an oxidant, H₂O₂. Its antiproliferative effect was concentration-dependent. ICI did not have a significant antiproliferative effect. PR-A, PR-B, AR, and FasL expression were all increased as compared with untreated cells. Conclusions: The cell line appears to be an adequate model for stromal components of endometriotic implants. That ICI has no inhibitory effect on endometrial proliferation may explain why a phase II clinical trial on its use to treat endometriosis did not advance to later stages. The upregulation of PR-B and AR may be responsible for antiproliferative effects induced by TSA, a histone deacetylase inhibitor (HDACI). HDACIs may be promising therapeutics in treating endometriosis due to their antiproliferative effects as well as the potential to restore gene dysregulation through chromatin remodeling.

show abstract

“…monocytes/macrophages of patients with endometriosis could promote development of endometriotic lesions by means of cytokine-stimulated cell activation and proliferation. This could be a compensatory mechanism due to the lack of the specific immune response [18,19]. The subpopulation of T lymphocytes, constitutively expressing high numbers of IL-2R (T cell growth factor receptor), so-called regulatory T cells (CD25?…”

Section: Discussionmentioning

confidence: 99%